Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HB05
- Development stage
- Unknown
- Lead developer
- HealthBiome
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
HB05 is a bacteriotherapy developed by HealthBiome, utilizing a specific strain of Akkermansia muciniphila (HB05) originally isolated from the breast milk of healthy Korean women. The product is developed both as a live biotherapeutic and as a postbiotic formulation known as HB05P. HB05P is created through a proprietary pasteurization process that heat-kills the bacteria while maintaining its functional properties, thereby enhancing safety and stability compared to live probiotic products. The mechanism of action involves modulating the gut microbiome and host metabolic and neuromuscular pathways. Clinical research has demonstrated that HB05P can significantly improve muscle strength and peak torque in elderly populations, specifically targeting sarcopenia. It is also being investigated for its potential in treating cognitive function disorders and metabolic diseases.
- Other names
- Akkermansia muciniphila HB05
Beyond the preview
Go deeper on HB05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HB05.